Up until recently, the stock has been a chronic underperformer.

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...

Pfizer Inc. Q4 shows post-COVID growth, Seagen-fueled oncology gains, and obesity upside. Click for this updated look at PFE ...

Pfizer Inc. (NYSE:PFE) is included among the 15 Large Cap Stocks with Highest Dividends. Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical ...

They aren't just "pandemic stocks." ...

Jim Cramer reviewed Pfizer Inc. (NYSE:PFE) while breaking down 16 stocks for a market facing higher energy costs and economic ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or ...

Recent developments in pharmaceutical research continue to shape Pfizer’s position within the healthcare sector. Shifts in external regulatory discourse and therapeutic progress remain central to ...

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC ("Tutanota") to purchase up to 1 million shares of Pfizer common stock at a ...

It’s rare to get such a massive high-yielder that’s also positioning itself for long-term growth. Of course, shares of Pfizer ...